Describe the genetic and molecular pathophysiology of malignant hyperthermia. List triggering agents. Outline the clinical features (CHCT/IVCT grading, MHAUS clinical grading scale). Describe the emergency management protocol including dantrolene dosing and post-crisis care.
Autosomal dominant; RYR1 mutations (~70%), CACNA1S (~1%). Normal contraction: T-tubule depolarisation → DHPR conformational change → RyR1 opens → controlled SR Ca²⁺ release → contraction → SERCA reuptake.
MH event: mutant RyR1 is abnormally sensitive/slow to close; trigger contact → massive uncontrolled Ca²⁺ release → sustained contraction (rigidity) → ATP consumed at enormous rate → anaerobic glycolysis → lactic acidosis → heat → hyperthermia → rhabdomyolysis → AKI, hyperkalaemia, arrhythmia.
| Sign | Details | Specificity |
|---|---|---|
| ↑ETCO₂ (EARLIEST sign) | Rapid rise despite adequate ventilation | Most sensitive early warning |
| Masseter rigidity | Jaw stiffness 30–60s after succinylcholine | Pathognomonic concern, cancel elective surgery |
| Tachycardia | HR 140–180 | Non-specific but common |
| Hyperthermia (NOT first sign) | May exceed 40°C, rises 1°C/3–5min | Late presentation indicates diagnostic delay |
| Muscle rigidity | Generalised, 'stiff as a board' | Highly specific under volatile anaesthesia |
| Metabolic acidosis | Mixed, lactate>10mmol/L | Combined with ↑ETCO₂ = strong indicator |
| Rhabdomyolysis | CK peaks 12–24h later | Confirms diagnosis retrospectively |
| Dantrolene | Detail |
|---|---|
| Mechanism | Binds FKBP12 → stabilises RyR1 in CLOSED state → stops uncontrolled Ca²⁺ release; only agent targeting the molecular defect |
| Initial dose | 2.5mg/kg IV bolus, repeat q5–10min to max 10mg/kg |
| Maintenance | 1mg/kg IV q4–6h for 24–48h — prevents recrudescence (can recur 24–36h later) |
| Preparation | 20mg/vial + 60mL sterile water/vial; 70kg pt at 2.5mg/kg needs ~9 vials |
Cooling: ice packs axillae/groin/neck, cold IV saline 4°C 15mL/kg, target <38.5°C. Hyperkalaemia: calcium gluconate, insulin+dextrose, bicarbonate. Rhabdomyolysis: fluids, urine alkalinisation to prevent AKI. Arrhythmia: procainamide/lidocaine, avoid CCBs.